|
|
Globally
about half of all marketed products and one third
of all pipeline in biotech/pharma business are formulated
using drug delivery (DD) technologies
(formulations other than simple oral tablet, capsule or injectable solution;
see graph). Therefore having comprehensive and
up-to-date DD information and analysis is business
essential
for
product development and licensing decisions.
PharmaCircle is the
only company that covers 1000+ companies
with DD technologies,
2800 DD
technologies, 7400+
DD
pipeline &
marketed products, 43,000+
DD patents, 17000+
DD deals,
acquisitions
and news and 1000+ DD researchers searchable in 180+ DD technology
categories.
-
Company Profiles:
Contact/address, year founded, business model,
capabilities, facility & manufacturing locations, therapeutic and DD
categories of focus, partners (product/technology),
history/dates of
acquisitions,
financials, chart of
pipeline/products by phase, separated as DD
and non-DD and a table for
DD technologies if any as well as a
table of
pipeline and products
sorted by phase, route and indications.
-
DD Technologies:
Description,
detailed analysis , patents,
deals&news ,
pipeline &products associated with the
technologies, etc.
-
DD Pipeline & Products:
Indications, phase, partners/territories, US/EU/JAP
labels, DD technology & excipients used, orphan drug status, combination
products, administration route (injectable,
oral,
transdermal, Inhalation and other 180+ categories),
frequency of administration,
dose, etc. All relevant FDA information is
integrated to the product info with hyperlinks (market/approval
dates and orange book
patent exclusivity, therapeutic equivalents, NDC packaging info,
etc.) (see
FDA info). For each pipeline and product
historical news as well as a summary of the clinical development results
from news releases are summarized with hyperlink to references. (see
Oral-lyn
1,2,3).
Product sales. royalty, licensing
and manufacturing revenues
and R&D cost for each project are extracted from the financial documents
and displayed in a table and graph as a function of year,
DD and
therapeutic categories.
-
Molecule:
Type (small organic,
peptide, protein, antibody, gene, oligonucleotide, siRNA, etc.) ,
mechanism, structure,
Molecular Weight ,
Water Solubility , pKa, logP, BCS
classification, bitterness, food and first pass effect, t1/2,
Vd, Cl, etc. with references (see
Fentanyl). Our powerful search engine
filters thousands of molecules by any of the above molecule properties
to identify potential product candidates in various drug delivery
categories (see an
example
search).
-
DD Deals & Acquisitions:
Organized by year, DD, therapeutic category, phase and territories. Also
full financial details are provided when available (see
deal search results).
-
DD Patents:
Organized by
year and DD category and the company that
owns them
-
DD University Researchers:
Organized by DD categories
-
White papers/expert reviews
of DD technologies in every major DD categories
(25+ white papers, each several hundred pages long) updates as the
information flows on a daily basis.
-
Customizable compare and contrast
tables
in every major DD technology category (34
Tables) is one of the most value added products of PharmaCircle that put
due diligence level info and analysis at your finger tips.
-
Daily newss
updates on all DD relevant news organized by
various categories and also
weekly newsletters
summarizing the events of the week as well as the update in the
database.
-
Extensive charts for data with 2-D and
3-D custom charting
capabilities makes our database interactive.
-
Products sales
values for the World, US, EX-US, Europe and Japan are provided from 1996
to 2008 for >750 products when available in the financial statements
organized by
DD
as well as therapeutic category (1,2,
3).
Royalty
and licensing vales are also provided for partnered programs along with
royalty calculations
-
Nearly 400 VC Companies and
their DD and Biotech/Pharma investments charted by business
model,
DD
and therapeutic category
-
Extensive search
capabilities
to search every details of company, DD technology, molecule,
pipeline/products, deals, news, patents and FDA content with auto-fill
capabilities (see
1, 2,
3, 4,
5)
-
Comprehensive and up-to-date pipeline/product,
molecule and drug delivery technology information and analysis
facilitates technology selection, formulation development, Life
Cycle Management (LCM), partnering, licensing and competitive
intelligence efforts
-
For companies with internal DD expertise, PharmaCircle's service
augments internal efficiency by providing a comprehensive, complete
and up to date drug delivery information and analysis database. Our
service costs at a fraction of what it would if performed internally
-
For biotechnology companies that cannot afford internal drug
delivery expertise, PharmaCircle's comprehensive drug delivery
information coupled with the broader analysis of the Pharma/Biotech
related information enhances the success of your pipeline and
products in today's competitive market landscape.
-
Drug delivery (DD) is a multidisciplinary field that incorporates
pharmaceutics, chemistry, biology and engineering (process/devices)
. Drug Delivery technologies are patent protected formulation
technologies that modifies drug release profile, absorption,
distribution and elimination for the benefit of improving product
efficacy & safety and patient convenience & compliance.
-
PharmaCircle data base considers all products except those immediate
release capsule/tablet/solution/suspension and simple injectable
solution/suspension products as drug delivery products. All
inhalation, nasal, ocular, topical, buccal and vaginal products are
counted as drug delivery products.
-
Convenience: Makes it more pleasant to take medications
-
Oral Rapidly Disintegrating Systems, etc.
-
Compliance:Motivates & makes it easier for patients to follow
their treatment courses.
-
Oral controlled release, injectable depot, inhaled proteins
-
Enhanced Efficacy: Targeted & optimized drug delivery
- PEGylated proteins,Liposomes, Nanoparticles, etc.
-
Product Safety -Minimizes drug in non-diseased areas
- Liposomes, injectable depot, nanoparticles, etc.
-
Creates & Extends Markets
- Successful commercialization of gene based medicines is
impossible without the use of drug delivery technology
- Life Cycle Management / LCM- Extended market exclusivity and
expanded market share at a minimum risk and cost
- Today, almost half of all marketed products sold
worldwide use Drug Delivery technologies
- In 2006, among the top 750 pharmaceutical Rx roducts sold world wide
38% incorporated Drug Delivery technologies with global sales
reaching well over $115 billion USD
- DD technologies are increasingly being applied
for NCEs (New Chemical Entity) and Life Cycle M projects
- Pure DD service company model is rapidly becoming
extinct
- Survival of formerly DD service companies now
depend on their success in DD product introductions
|
| Number Marketed and Development Products with or without DD Technologies | |
NCE Pipeline Marketed Products Non NCE Pipeline | | | | Number of Products | | | D=Drug Delivery P=Pharma/Biotechnology |
Overall Market Trends
- Pure Drug Delivery service company model is rapidly becoming
extinct. The survival of formerly Drug Delivery service companies
now depend on their success in Drug Delivery product
introductions
-
Drug Delivery technologies are now being applied increasingly
by large pharmaceutical, biotechnology, specialty pharma
and
generic companies in the development of value added products
- Product introductions incorporating drug delivery technologies will
increase at an accelerating rate in the years ahead
-
Drug Delivery technologies are becoming integral part of
New Chemical Entity (NCE) development
Oral Delivery:
-
Modified release technologies are routinely applied to
products in early stages of development, New Chemical Entity
(NCE)’s and generics
-
Growth in convenient dosage forms; rapidly disintegrating
dosage forms, etc. will continue
-
Growth in products using water insoluble Drug Delivery
technologies;
lipid based and nanocrystals will continue
-
Interest in oral delivery of proteins will
continue
Skin Delivery (Transdermal):
-
More technologies will be available to deliver increasing
amounts of small and large molecular weight drugs through the
skin
-
Products incorporation skin poration technologies should
start appearing in the market within the next 5 to 10 years
Inhalation/Nasal Delivery:
-
Inhalation field is already a mature Drug Delivery
segment will increasingly be used for local as well as systemic
delivery of small and large molecules (protein, peptide, gene,
siRNA, etc.)
-
Nasal route has utility in delivering some drugs directly
into brain
and advances in nasal delivery devices to improve brain and
systemic drug delivery will continue.
Injectable Delivery:
-
Injectable depot technologies will increasingly be used for
chronically administered small as well as large molecules
-
Liposomes, nanoparticles PEG/polymer prodrugs,
etc. will increasingly be applied for targeted delivery of small and
large molecular drugs to create new/incremental markets for cancer
and other chronic diseases
-
More technologies will be available for effective and safe
delivery of genes, oligonucleotides and siRNA using viral
and non- viral Drug Delivery technologies
-
Controlled release beyond once day may be a reality if the
dosage form can be retained longer in the stomach or GI tract.
Stomach retentive technologies will get more attention for this
purpose
-
Effective and safe technologies for targeted delivery of cancer
drugs,
genes and oligonucleotides/siRNA
- Effective and safe brain drug delivery
technologies
- Quest for oral delivery of macromolecules
will continue
|
|
What
is Drug Delivery?
